Search

PTC Therapeutics Inc

Затворен

СекторЗдравеопазване

71.43 -0.71

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

70.48

Максимум

72.06

Ключови измерители

By Trading Economics

Приходи

86M

83M

Продажби

88M

361M

P/E

Средно за сектора

7.597

57.002

EPS

0.92

Марж на печалбата

23.16

Служители

991

EBITDA

198M

162M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+37.68% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-59M

6.2B

Предишно отваряне

72.14

Предишно затваряне

71.43

Настроения в новините

By Acuity

16%

84%

35 / 340 Класиране в Healthcare

PTC Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 19:46 ч. UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13.08.2026 г., 19:36 ч. UTC

News
Social Media

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12.08.2026 г., 23:51 ч. UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11.08.2026 г., 19:46 ч. UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10.08.2026 г., 19:46 ч. UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7.08.2026 г., 21:02 ч. UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6.08.2026 г., 19:56 ч. UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5.08.2026 г., 19:26 ч. UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4.08.2026 г., 20:07 ч. UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3.08.2026 г., 19:46 ч. UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31.07.2026 г., 21:01 ч. UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30.07.2026 г., 22:31 ч. UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29.07.2026 г., 18:26 ч. UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28.07.2026 г., 18:31 ч. UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27.07.2026 г., 20:06 ч. UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22.07.2026 г., 17:16 ч. UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21.07.2026 г., 18:01 ч. UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20.07.2026 г., 19:56 ч. UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Сравнение с други в отрасъла

Ценова промяна

PTC Therapeutics Inc Прогноза

Ценова цел

By TipRanks

37.68% нагоре

12-месечна прогноза

Среден 99.09 USD  37.68%

Висок 130 USD

Нисък 70 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за PTC Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

9

Купи

1

Задържане

1

Продай

Настроение

By Acuity

35 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat